mRNA vaccines now preferred for both doses, NACI says

About This Source - CBC News

CBC News is the division of the Canadian Broadcasting Corporation responsible for the news gathering and production of news programs on the corporation’s English-language operations, namely CBC Television, CBC Radio, CBC News Network, and CBC.ca.

CBC News is the largest news broadcaster in Canada. It frequently collaborates with its French-language counterpart, Radio-Canada Info, although the two are organizationally separate.

Recent from CBC News:

  • N.L. premier says federal-provincial Muskrat Falls deal gives ‘breathing room’
  • Nishnawbe Aski Nation disappointed after meeting Ford government about Ontario wildfires
  • B.C. residents sound alarm over proposed water bottling plant near village
  • CBC News published this video item, entitled “mRNA vaccines now preferred for both doses, NACI says” – below is their description.

    The National Advisory Committee on Immunization is recommending the provinces stop administering the AstraZeneca-Oxford vaccine in most cases — and AstraZeneca recipients should instead receive a second dose of an mRNA vaccine. “This is a discretionary recommendation,” said Dr. Dirk Huyer, Ontario’s outbreak response co-ordinator.

    CBC News YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    In This Story: AstraZeneca

    AstraZeneca plc/AB (LON: AZN) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America.

    3 Recent Items: AstraZeneca

  • COVID -19: Kenya’s COVID vaccine supply is dwindling
  • Infectious diseases expert to run for Labor at federal election | 9 News Australia
  • Melbourne grandmother treated for blood clotting in ICU | Coronavirus | 9News Australia
  • Leave a Comment